Inogen (INGN)
Provides portable oxygen and respiratory devices through consumer, provider, and distributor channels.
Something off on this page? Send us feedback.
Generates revenue from portable oxygen concentrators, airway clearance, stationary oxygen, and CPAP-mask products. U.S. direct-to-consumer sales and rentals sit alongside sales through home medical equipment and distribution channels, including an international footprint.
Portable oxygen concentrators under the Inogen One and Inogen Rove brands provide supplemental long-term oxygen therapy for people with chronic respiratory conditions. The portfolio also includes the Simeox airway-clearance system, Voxi 5 stationary oxygen concentrators, and Aurora CPAP masks.
In the United States, products are sold and rented directly to consumers and sold through home medical equipment providers, distributors, and resellers. Outside the United States, sales run through distributors, resellers, home medical equipment providers, and large house accounts across many countries.
Research and development focuses on functionality, ease of use, total cost of ownership, next-generation concentrators, and Simeox. The business depends on regulated-device manufacturing, quality systems, commercial channels, and respiratory-product development.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 22, 2025 | Needham | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $105.5M · Total debt $15.8M · Total assets $285.6M · Shareholders' equity $174.9M
- Revenue
- $95.1M
- Operating income
- −$5.1M
- Net income
- −$3.9M
No dividends on record.
| Institutions | 71.32% | 19.31M shares | |
|---|---|---|---|
| 128 holders · as of Jun 30, 2026 | |||
| Insiders | 8.37% | 2.27M shares | |
| 14 holders · as of Sep 3, 2026 | |||
| Strategic holders | 26.80% | 7.26M shares | |
| 3 holders · as of Feb 24, 2025 | |||
| Adds to | 106.49% | ||
27.07M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 106.49%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Novo Holdings A/S (formerly known as Novo A/S)Strategic | 13.11% | 3.55M | filed Feb 2, 2018 |
Yuwell (Hong Kong) Holdings LimitedStrategic | 9.70% | 2.63M | filed Feb 24, 2025 |
BlackRock, Inc.Institution | 6.46% | 1.75M | as of Jun 30, 2026 |
Steven A. CohenInsider | 4.75% | 1.29M | filed Feb 14, 2019 |
Acadian Asset Management LLCInstitution | 4.05% | 1.10M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 1, 2026 | Boyer Jennifer M. Yi | officer: EVP Entrprs Enblmnt, Ch HR Off | −10,938 | $6.60 |
| May 29, 2026 | Boyer Jennifer M. Yi | officer: EVP Entrprs Enblmnt, Ch HR Off | −10,770 | $6.53 |
- ResMed
Mobi POC overlaps in portable long-term oxygen therapy
- Philips (ADR)
Respironics POC placements retain a narrower oxygen overlap
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Inogen | $5.05 | −3.40% | $141.6M | — | — | 0.4 | +3.0% |
| ResMed | $222.36 | +0.18% | $32.20B | 21.3 | 18.3 | 5.7 | +8.6% |
| Philips (ADR) | $24.52 | −1.82% | $24.41B | 18.9 | 12.8 | 1.2 | −2.8% |
| Median | 20.1 | 15.6 | 3.5 | +2.9% |